a starters guide
Three of the most widely discussed treatments—Semaglutide, Tirzepatide, and Retatrutide—
share similarities in form and function but differ in their mechanisms, benefits, and outcomes.
How These GLP's Work
GLP-1, GIP, and Glucagon Explained
Each of these injectables works by mimicking the natural hormones that regulate appetite, insulin release, and metabolism.
Semaglutide
Semaglutide targets GLP-1 receptors, helping to increase insulin when blood sugar is high, reduce glucagon (which raises blood sugar), slow digestion, and enhance feelings of fullness.
Tirzepatide
Tirzepatide activates both GLP-1 and GIP receptors. This dual action enhances insulin sensitivity, boosts fat metabolism, and delivers stronger appetite control than GLP-1 treatments alone.
Retatrutide
Retatrutide represents the newest generation of metabolic medications. It stimulates three hormone receptors simultaneously—leading to more effective calorie burning, appetite suppression, and broader metabolic improvements.
Benefits and Effectiveness
for Weight Loss and Blood Sugar Control
Each of these medications offers impressive benefits, but their clinical focus and outcomes vary.
Semaglutide
Proven effective for both type 2 diabetes and weight management, often achieving an average 10–15% body weight reduction.
Tirzepatide
Known for even greater results—up to 20%+ weight loss in studies—while providing powerful improvements in blood sugar control.
Retatrutide
Designed primarily for weight reduction and metabolic health, with trials showing over 24% average body weight reduction and significant increases in energy expenditure.
Dosing & Side Effects
dosing
Each treatment is a once-weekly subcutaneous injection, offering convenience and long-lasting results.
Semaglutide
Typically starts at 0.25 mg weekly, increasing up to 2.4 mg for weight management.
Tirzepatide
Starts at 2.5 mg weekly, increasing to 15 mg based on response.
Retatrutide
Begins at 2 mg weekly, titrated up to 8 mg or higher depending on tolerance.
Side Effects
Most users experience mild gastrointestinal symptoms—nausea, vomiting, or diarrhea—during the dose adjustment phase.
Semaglutide
Usually well tolerated after initial weeks.
Tirzepatide
May cause stronger appetite changes during early stages.
Retatrutide
May cause more pronounced early GI effects due to its triple action.
comparison
SEMAGLUTIDE VS TIRZEPATIDE VS RETRUTIDE
| Feature | Semaglutide | Tirzepatide | Retatrutide |
| Brand Name(s) | Ozempic & Wegovy | Mounjaro & Zepbound | *Still in Phase 3 Trials |
| Hormone Targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Mechanism | Single receptor agonist | Dual receptor agonist | Triple receptor agonist |
| Indications | Type 2 diabetes, weight loss | Type 2 diabetes, weight loss | Weight loss, metabolic health |
| Dosing Frequency | Weekly | Weekly | Weekly |
| Typical Dosage Range | 0.25–2.4 mg | 2.5–15 mg | 2–8 mg+ |
| Weight Loss Efficacy | 10–15% (52 weeks) | 15-20%(52 weeks) | Up to 24% (in clinical studies) |
| Blood Sugar Control | Strong | Very strong | Strong (secondary) |
| Cardiovascular Benefits | Proven | Proven | Promising |
| Side Effects | Mild GI discomfort | Appetite changes, GI effects | GI effects |
| Delivery Format | Pen or cartridge | Pen only | Pen only |